Study design of ESCAPE-TRD, a long-term, comparative, randomised phase IIIb clinical trial of esketamine nasal spray in treatment resistant depression

Neuroscience Applied, vol. 1, pp. 100638

Authors 10

1. A. Reif

   University Hospital Frankfurt

   Affiliation as printed

   1University Hospital Frankfurt, Department of Psychiatry, Frankfurt, United Kingdom

2. T. Messer

   Technical University of Munich

   Affiliation as printed

   2Technische Universität München, Danuvius Klinik GmbH, Pfaffenhofen an der Ilm, Germany

3. P. Eckhard

   Janssen (Germany)

   Affiliation as printed

   3Janssen Germany, Not appliable, Neuss, Germany

4. K. Heerlein

   Janssen (Germany)

   Affiliation as printed

   4Janssen Global Services, Not applicable, Neuss, Germany

5. R. Milz
   Affiliation as printed

   5Janssen, Not applicable, Titusville, United States

6. B. Rive

   Janssen (France)

   Affiliation as printed

   6Janssen EMEA, Not applicable, Paris, France

7. G. Van Dooren

   Janssen (Belgium)

   Affiliation as printed

   7Janssen EMEA, Not applicable, Beerse, Belgium

8. Christian von Holt

   Janssen (Germany)

   Affiliation as printed

   4Janssen Global Services, Not applicable, Neuss, Germany

9. R. Wapenaar Aachen 8Janssen EMEA

   Janssen (Netherlands)

   Affiliation as printed

   8Janssen EMEA, Not applicable, Breda, Netherlands- The

10. Yordan Godinov

    Bulgarian National Bank

    Affiliation as printed

    9Janssen EMEA, Not applicable, Sofia, Bulgaria